Suppr超能文献

继发性高血压识别的改进:采用系统方案

Improved identification of secondary hypertension: use of a systematic protocol.

作者信息

Kotliar Carol, Obregón Sebastián, Koretzky Martin, Botto Fernando, Di Leva Ana, Boscaro Marcelo, Ali Ayan, Ferdinand Keith C

机构信息

Center of Hypertension, Austral University Hospital, Buenos Aires, Argentina.

Santa María de la Salud, Center for the Prevention of Hypertension, Dyslipidemia and Diabetes, San Isidro, Buenos Aires, Argentina.

出版信息

Ann Transl Med. 2018 Aug;6(15):293. doi: 10.21037/atm.2018.06.25.

Abstract

BACKGROUND

The accurate identification and diagnosis of secondary hypertension is critical, especially while atherosclerotic cardiovascular heart disease continues to be the leading cause of death in the industrialized world. Nevertheless, despite the existence of diagnostic tools, there are significant variations of the estimated prevalence of secondary hypertension, due to multiple etiologies and suboptimal recognition. This study demonstrates the results of using a systematic and protocolled approach to improve recognition of the presence of secondary hypertension. In the future, this questionnaire can be a quick and effective tool to unveil secondary hypertension in a broad array of clinical settings.

METHODS

A total of 28,633 consecutive patients from January 1, 2007 to January 1, 2017 were diagnosed as having primary or secondary hypertension, utilizing the International Code of Diseases. Patients were located at the Center of Hypertension, Institute of Cardiology at Austral University Hospital, Buenos Aires, Argentina and were then further classified as having TRH, or non-resistant hypertension, to which a systematic protocol was employed in search for secondary hypertension. The confirmation of secondary hypertension was subsequently confirmed by diagnostic laboratory and imaging techniques in a hospital setting.

RESULTS

A final population of 12,284 patients with treatment resistant hypertension (TRH) and non-treatment resistant hypertension (NTRH) were included in this study, where an etiology of secondary hypertension was identified in 50.9% and 36% of patients in each treatment group, respectively. Physicians used confirmatory laboratory testing and imaging of patients who were identified as having a cause for their secondary hypertension, with no significant differences in sex, age and body mass index (BMI) among study groups.

CONCLUSIONS

These results illustrate the prevalence and distribution of the causes of secondary hypertension using a systematic, protocolled approach, which revealed a higher percentage of secondary hypertension than previously reported. This tool may be used by healthcare providers to ensure the appropriate recognition of secondary causes of hypertension in a wider range of patients with high blood pressure beyond resistant hypertension, changing the diagnostic paradigm of this condition.

摘要

背景

继发性高血压的准确识别和诊断至关重要,尤其是在动脉粥样硬化性心血管疾病仍是工业化国家主要死因的情况下。然而,尽管存在诊断工具,但由于多种病因和识别欠佳,继发性高血压的估计患病率仍存在显著差异。本研究展示了采用系统且标准化方法提高继发性高血压识别率的结果。未来,这份问卷可成为在广泛临床环境中揭示继发性高血压的快速有效工具。

方法

利用国际疾病分类法,对2007年1月1日至2017年1月1日期间连续就诊的28,633例患者进行原发性或继发性高血压诊断。这些患者来自阿根廷布宜诺斯艾利斯澳大利亚大学医院心脏病学研究所高血压中心,随后被进一步分类为患有治疗抵抗性高血压(TRH)或非抵抗性高血压,针对TRH采用系统方案来寻找继发性高血压病因。继发性高血压随后在医院环境中通过诊断性实验室和影像学技术得以确诊。

结果

本研究纳入了最终的12,284例治疗抵抗性高血压(TRH)和非治疗抵抗性高血压(NTRH)患者,每个治疗组中分别有50.9%和36%的患者被确定为继发性高血压病因。医生对被确定为有继发性高血压病因的患者进行了确证性实验室检测和影像学检查,各研究组在性别、年龄和体重指数(BMI)方面无显著差异。

结论

这些结果说明了采用系统、标准化方法时继发性高血压病因的患病率和分布情况,显示出继发性高血压的比例高于先前报告。医疗保健提供者可使用此工具,以确保在更广泛的高血压患者(而非仅抵抗性高血压患者)中正确识别继发性高血压病因,从而改变这种疾病的诊断模式。

相似文献

2
7
Commentary on: "Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial." Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR, CA184-043 Investigators. Departments of Urology and Immunology and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA, Electronic address: kwon.eugene@mayo.edu; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and Brady Urological Institute, Baltimore, MD, USA; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA; Institut Gustave Roussy, University of Paris-Sud, Villejuif, France; Institut Gustave Roussy, Villejuif, France; VU University Medical Centre, Amsterdam, Netherlands; Vienna General Hospital, Medical University Vienna, Vienna, Austria; Institut Bergonié, Bordeaux, France; CHU Caremeau, Nimes, France; Centro Médico Austral, Buenos Aires, Argentina; Centre Jean Perrin, Clermont-Ferrand, France; St John of God Hospital, Subiaco, WA, Australia; University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy; Hospital de Caridade de Ijuí, Ijuí, Brazil; Nottingham University Hospital, Nottingham, UK; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Institute of Oncology Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania; Hospital Británico de Buenos Aires, Buenos Aires, Argentina; Herlev Hospital, Herlev, Denmark; Odense University Hospital, Odense, Denmark; University of Texas MD Anderson Cancer Center, Houston,关于“多西他赛化疗后进展的转移性去势抵抗性前列腺癌患者放疗后伊匹木单抗与安慰剂对比研究(CA184 - 043):一项多中心、随机、双盲、3期试验”的述评。权恩东(Kwon ED)、德雷克·C·G(Drake CG)、舍尔·H·I(Scher HI)、菲扎齐·K(Fizazi K)、博西·A(Bossi A)、范登·埃尔特韦赫·A·J(van den Eertwegh AJ)、克莱纳·M(Krainer M)、胡德·N(Houede N)、桑托斯·R(Santos R)、马哈梅迪·H(Mahammedi H)、吴思(Ng S)、马约·M(Maio M)、弗兰克·F·A(Franke FA)、桑达尔·S(Sundar S)、阿加瓦尔·N(Agarwal N)、伯格曼·A·M(Bergman AM)、丘莱亚努·T·E(Ciuleanu TE)、科尔本费尔德·E(Korbenfeld E)、森格洛夫·L(Sengeløv L)、汉森·S(Hansen S)、洛戈塞蒂斯·C(Logothetis C)、比尔·T·M(Beer TM)、麦克亨利·M·B(McHenry MB)、加尼耶·P(Gagnier P)、刘丹(Liu D)、格里特森·W·R(Gerritsen WR),CA184 - 043研究团队。美国明尼苏达州罗切斯特市梅奥诊所泌尿外科、免疫学系及梅奥诊所综合癌症中心,电子邮箱:kwon.eugene@mayo.edu;美国马里兰州巴尔的摩市约翰·霍普金斯西德尼·金梅尔综合癌症中心及布雷迪泌尿外科研究所;美国纽约州纽约市纪念斯隆凯特琳癌症中心及威尔康乃尔医学院;法国巴黎 - 萨克雷大学古斯塔夫·鲁西研究所,维勒瑞夫;法国古斯塔夫·鲁西研究所,维勒瑞夫;荷兰阿姆斯特丹VU大学医学中心;奥地利维也纳医科大学维也纳总医院;法国波尔多贝戈涅研究所;法国尼姆卡勒莫医院;阿根廷布宜诺斯艾利斯澳大利亚医学中心;法国克莱蒙费朗让·佩兰中心;澳大利亚西澳大利亚州苏比亚科圣若翰医院;意大利锡耶纳大学医院、托斯卡纳肿瘤研究所;巴西伊茹伊慈善医院;英国诺丁汉大学医院;美国犹他州盐湖城犹他大学亨茨曼癌症研究所;荷兰阿姆斯特丹荷兰癌症研究所及安东尼·范·列文虎克医院;罗马尼亚克卢日 - 纳波卡肿瘤研究所及尤利乌·哈蒂根努医科药学院;阿根廷布宜诺斯艾利斯英国医院;丹麦赫勒夫医院;丹麦欧登塞大学医院;美国得克萨斯大学MD安德森癌症中心,休斯顿
Urol Oncol. 2016 May;34(5):249-50. doi: 10.1016/j.urolonc.2015.03.013. Epub 2015 Apr 20.
10
Tertiary work-up of apparent treatment-resistant hypertension.对明显难治性高血压的三级检查
Blood Press. 2016 Oct;25(5):312-8. doi: 10.3109/08037051.2016.1172865. Epub 2016 Apr 28.

本文引用的文献

3
Secondary arterial hypertension: when, who, and how to screen?继发性动脉高血压:何时、针对谁以及如何筛查?
Eur Heart J. 2014 May 14;35(19):1245-54. doi: 10.1093/eurheartj/eht534. Epub 2013 Dec 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验